News | April 22, 2022
WHO recommends Paxlovid for Covid-19 therapy
This recommendation is based on new data from two randomized controlled trials involving 3078 patients
This recommendation is based on new data from two randomized controlled trials involving 3078 patients
Pre-exposure prevention trial reduced risk of symptomatic Covid-19, with no severe disease or Covid-19-related deaths in the Evusheld group
Immune response confirmed in stand-alone influenza vaccine and combination vaccine with a potential path forward for both
The purpose of the study is to investigate safety and tolerability of SNIPR001 in healthy volunteers and to evaluate the effect of SNIPR001 on reducing E. coli colonization in the gut
Turn has developed a novel cell rejuvenating platform with significant potential for application in an array of age-related diseases
This could be a game-changer for the prevention of the disease; seeing more doses of the life-saving jab reach more girls
GRC 54276 has shown tumour cell killing ability in preclinical studies as a single agent and as well in combination with checkpoint inhibitors, making it a high-priority target in immuno-oncology
Daewoong Pharmaceutical, HanAll Biopharma join Astellas Venture Management and other VCs in oversubscribed funding round to accelerate Turn Bio's preclinical advances in multiple therapeutic areas
Under the manufacturing agreement, Lonza will provide drug substance for Asher Bio's cis-targeted IL-2 fusion protein
Both mRNA-1020 and mRNA-1030 target hemagglutinin and neuraminidase antigens, two major influenza surface glycoproteins that are essential across the viral life cycle
Subscribe To Our Newsletter & Stay Updated
